7/19/2018 Lebrikizumab - DrugBank
Lebrikizumab
Targets (2)
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
IDENTIFICATION
Name Lebrikizumab
Accession Number DB11914 (DB05962)
Type Biotech
Groups
Investigational
Biologic Classification Protein Based Therapies Monoclonal antibody (mAb)
Description Lebrikizumab has been used in trials studying the treatment of Asthma, Allergic Asthma, Atopic Dermatitis, Idiopathic Pulmonary Fibrosis, and COPD, Chronic Obstructive Pulmonary Disease.
Protein chemical formula
Not Available https://www.drugbank.ca/drugs/DB11914 1/9 7/19/2018 Lebrikizumab - DrugBank
Protein average weight Not Available
Sequences Not Available
Synonyms Not Available
External IDs
TNX-650
Categories Not Available
UNII
U9JLP7V031
CAS number
953400-68-5
PHARMACOLOGY
Indication Not Available
Pharmacodynamics
Not Available
Mechanism of action Anti-IL-13 humanized monoclonal antibody Lebrikizumab binds to and blocks the activity of IL-13, which may result in the inhibition of Hodkin lympoma cell proliferation. IL-13 cytokine, an important mediator in allergic inflammation, may be an autocrine growth factor for Hodgkin lymphoma cells.
https://www.drugbank.ca/drugs/DB11914 2/9 7/19/2018 Lebrikizumab - DrugBank
U Interleukin-13
Not Available
Human
U IL13 protein
Not Available
Human
Absorption Not Available
Volume of distribution Not Available
Protein binding Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity Not Available
Affected organisms Not Available
Pathways Not Available
https://wwwh .drugbank.ca/drugs/DB1i 1914ff / 3/9 7/19/2018 Lebrikizumab - DrugBank Pharmacogenomic Effects/ADRs
Not Available
INTERACTIONS
Drug Interactions
Not Available
Food Interactions Not Available
REFERENCES
General References Not Available
External Links PubChem Substance
347911256
Wikipedia Lebrikizumab
CLINICAL TRIALS
Clinical Trials
Search
PHASE ↑↓ STATUS ↑↓ PURPOSE ↑↓ CONDITIONS ↑↓ COUNT ↑↓ 1 Completed Treatment Healthy Volunteers 2
1, 2 Unknown Treatment Lymphoma, Hodgkins 1 Status
2 Completed Treatment Asthma Bronchial 5
2 Completed Treatment Asthma, Allergic 1
2 Completed Treatment Atopic Dermatitis (AD) 2
https://www.drugbank.ca/drugs/DB11914 4/9 7/19/2018 Lebrikizumab - DrugBank
2 Completed Treatment Chronic Obstructive Pulmonary 1 Disease (COPD)
2 Completed Treatment Idiopathic Pulmonary Fibrosis (IPF) 1
2 Recruiting Treatment Atopic Dermatitis (AD) 1
2 Terminated Treatment Asthma Bronchial 1
3 Completed Treatment Asthma Bronchial 4
Showing 1 to 10 of 11 entries ‹ ›
PHARMACOECONOMICS
Manufacturers
Not Available
Packagers
Not Available
Dosage forms Not Available
Prices Not Available
Patents Not Available
PROPERTIES
State Not Available
Experimental Properties Not Available
TAXONOMY https://www.drugbank.ca/drugs/DB11914 5/9 7/19/2018 Lebrikizumab - DrugBank
Description Not Available
Kingdom
Organic Compounds
Super Class Organic Acids
Class
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Peptides
Alternative Parents Not Available
Substituents Not Available
Molecular Framework
Not Available
External Descriptors
Not Available
TARGETS
1. Interleukin-13
Kind
https://www.drugbank.ca/drugs/DB11914 6/9 7/19/2018 Lebrikizumab - DrugBank Protein
Organism Human
Pharmacological action
Unknown General Function
Interleukin-13 receptor binding
Specific Function
Cytokine. Inhibits inflammatory cytokine production. Synergizes with IL2 in regulating interferon-gamma synthesis. May be critical in regulating inflammatory and immune responses.
Gene Name IL13
Uniprot ID P35225
Uniprot Name
Interleukin-13
Molecular Weight 15815.585 Da
2. IL13 protein
Kind
Protein
Organism
Human
Pharmacological action
Unknown General Function Not Available
Specific Function
Not Available https://www.drugbank.ca/drugs/DB11914 7/9 7/19/2018 Lebrikizumab - DrugBank Gene Name
IL13
Uniprot ID
Q4VB53
Uniprot Name
IL13 protein
Molecular Weight
9044.53 Da
Drug created on October 20, 2016 15:00 / Updated on July 02, 2018 19:29
About About DrugBank
DrugBank Blog
Wishart Research Group Terms of Use
Privacy Policy
Support
FAQ
Help Email Support
Commercial Products
API Pricing API Docs
Data Licenses
Support
https://www.drugbank.ca/drugs/DB11914 8/9 7/19/2018 Lebrikizumab - DrugBank This project is supported by the Canadian Institutes of Health Research (award #111062), Alberta Innovates - Health Solutions, and by The Metabolomics Innovation Centre (TMIC), a nationally-funded research and core facility that supports a wide range of cutting-edge metabolomic studies. TMIC is funded by Genome Alberta, Genome British Columbia, and Genome Canada, a not-for-profit organization that is leading Canada's national genomics strategy with funding from the federal government. Maintenance, support, and commercial licensing is provided by OMx Personal Health Analytics, Inc. Designed by Educe Design & Innovation Inc.
https://www.drugbank.ca/drugs/DB11914 9/9